{"entity":{"id":"curie-siopen-score","kind":"term","name":"MIBG Curie and SIOPEN scores","aka":["Curie score","SIOPEN score","MIBG score","MIBG avidity","MIBG-avid","MIBG-non-avid","semi-quantitative MIBG scoring","123I-MIBG scan","MIBG scintigraphy","18F-MFBG PET","MFBG PET"],"tldr":"Neuroblastoma soaks up MIBG, a radioactive cousin of noradrenaline; the Curie and SIOPEN scores count how many body regions still light up on the scan, and a score that has not fallen enough after the first rounds of chemotherapy marks a child who is unlikely to be cured with the standard plan.","summary":"What is measured: the extent of MIBG-avid disease on a whole-body scan. How: iodine-123 MIBG planar and SPECT imaging (with a bone scan or FDG PET for the roughly 10 percent of tumours that do not take up MIBG); the Curie score grades nine skeletal segments and one soft-tissue site from 0 to 3 (maximum 30) and the SIOPEN score grades twelve skeletal segments from 0 to 6 (maximum 72). What a result changes: at diagnosis it stages metastatic disease and establishes MIBG avidity for later iodine-131 MIBG therapy; after induction, a Curie score above 2 (COG A3973) or a SIOPEN score above 3 predicts worse event-free survival in high-risk disease and is used to stratify and to select patients for intensified or experimental arms, such as adding iodine-131 MIBG in COG ANBL1531; the International Neuroblastoma Response Criteria of 2017 use MIBG to score skeletal response. Fluorine-18 MFBG PET, a same-day tracer with higher resolution, is replacing MIBG in trials. Where it matters: neuroblastoma and high-risk neuroblastoma.","asOf":"2026-09-17","links":[],"tags":[],"related":["mibg-theranostics","i131-mibg","inrg-staging","urinary-catecholamines","fdg-pet","dinutuximab"],"cancers":["neuroblastoma","neuroblastoma-high-risk"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"category":"Biomarkers"},"route":"/terms/curie-siopen-score/","neighbours":{"technology":[{"id":"fdg-pet","kind":"technology","name":"FDG PET","route":"/technologies/fdg-pet/"},{"id":"mibg-theranostics","kind":"technology","name":"MIBG imaging and 131I-MIBG therapy","route":"/technologies/mibg-theranostics/"}],"drug":[{"id":"i131-mibg","kind":"drug","name":"131I-MIBG (iobenguane I-131) therapy","route":"/drugs/i131-mibg/"},{"id":"dinutuximab","kind":"drug","name":"Dinutuximab (ch14.18) / dinutuximab beta","route":"/drugs/dinutuximab/"}],"term":[{"id":"inrg-staging","kind":"term","name":"INRG staging and risk groups","route":"/terms/inrg-staging/"},{"id":"urinary-catecholamines","kind":"term","name":"Urinary catecholamine metabolites (VMA and HVA)","route":"/terms/urinary-catecholamines/"}],"cancer":[{"id":"neuroblastoma-high-risk","kind":"cancer","name":"High-risk neuroblastoma","route":"/cancers/neuroblastoma-high-risk/"},{"id":"neuroblastoma","kind":"cancer","name":"Neuroblastoma (paediatric)","route":"/cancers/neuroblastoma/"}]}}